Metformin: Professor Of Medicine Says It’s Not Anti-Aging, But Is Something Else

Metformin - Professor Of Medicine Says It's Not Anti-Aging, But Is Something Else

From several reports, you’ve probably seen that the miracle drug Metformin is supposedly anti-aging. However, this professor says otherwise. He suggests that longer life is just a by-product of this drug’s true nature.

Metformin is a Type-2 Diabetes medication. Pharmacologists have found that it has certain anti-aging attributes. However, that may not be the actual function. Duke University associate professor Matthew Hirschey says that’s Metformin doesn’t directly improve a person’s life-span. That’s the “consequence” of its treatment, a person’s health-span. Metformin focuses on clearing a person’s illness and improving his or her health, rather than being “anti-aging.”

You can watch his interview in the video below.

As is mentioned in the WNCN – News interview, Professor Hirschey mentions that Metformin has been proven to increase the health in animals.

“They’re actually extending the health span of the animal, the organism, the person. So, instead of let’s say developing cardiovascular disease and dying of a heart attack, you don’t develop cardiovascular disease and therefore you don’t die of a heart attack. And therefore you happen to live longer as well.”

This diabetes wonder drug is assuredly approved by the Food and Drug Administration. And research facilities have been cleared to continue extensive testing on its effects within people.

The professor mentions that metabolic dysfunction is a main cause of disease and cancer within the body. Accordingly, Metformin targets the person’s metabolism, rectifying it, and helping it to combat disease in such a way.

Clinical trials are set to begin in 2016. The source reports that 3,000 people will be patients, and the target age is between 70 and 80 years old. Professor Hirschey continues the interview as follows.

“I think people, especially Americans, really like this idea of taking a pill to help them. And so again I think that sort of coupled with some of these other lifestyle interventions is going to be the best sort of long term approach.”

While longevity is a great “side effect” of Metformin, the professor mentions that it wouldn’t be the only outcome that is measured. He says that studying a chemical compound like this would take a long time. So, with that being the case, they would prefer to take on several parameters.

Although he mentions that some people are currently taking the drug recreationally, the professor says that it would be a while before general consumers would ever see Metformin as an over-the-counter pill — or something you see on the vitamin aisle of a store.

While research teams feel that the drug could be a modern miracle when applied to other illnesses, there are some that aren’t budging, like blood sugar levels in teens with Type-1 Diabetes. A study involved 140 patients with the diabetic disease, as says the Journal of the American Medical Association.

Nonetheless, regardless which companies fight over research grants and opportunities, one thing is for sure. Research teams are getting paid as much as $15 million to conduct studies within this field. One such research team is called Enlibrium.

This San Diego-based company has opened a collaboration with the University of California – Los Angeles. MedCity News reports that enlibrium CEO David Campbell mentioned as follows.

“The reason UCLA researchers – and Enlibrium – are looking for metformin analogs is because while the drug reduces energy, or ATP, production in some cells, it’s a very small subset. Only the cancers that express certain transporters are able to allow metformin to enter the cells and do the work. By engineering similar molecules that can enter a wider range of cancers, the drug and its analogs can do similar work in a range of cancers.”

When Metformin becomes available for the general public, as a health enhancement, will you try it? Feel free to share your thoughts in the comments.

[Photo by Robert Taylor/Flickr Images]